Early multi-cancer detection using liquid biopsy: emerging biomarkers and clinical strategies
-
By
-
Sowhanur Rahman Nirob
-
Md Kishor Morol
-
Diya Rahman
-
Liew Tze Hui
-
Dip Nandi
-
Mashiour Rahman
-
Abdullah Al Jubair
-
July 3, 2026
-
Clinical Scorecard: Advancements in Liquid Biopsy for Early Detection of Multiple Cancers: New Biomarkers and Clinical Approaches
At a Glance
| Category | Detail |
|---|
| Condition | Multiple Cancers |
| Key Mechanisms | Liquid biopsy utilizes circulating tumor material in biofluids for dynamic monitoring of tumor evolution and treatment responses. |
| Target Population | Patients at risk for multiple cancers requiring early detection. |
| Care Setting | Oncology and diagnostic laboratories. |
Key Highlights
- Liquid biopsy offers a non-invasive alternative to traditional tissue biopsy.
- Technologies like next-generation sequencing and digital PCR enhance analytical sensitivity.
- Multi-cancer early detection (MCED) aims to identify multiple cancers from a single blood sample.
- Machine learning and AI improve early cancer prediction and treatment stratification.
- Liquid biopsy can monitor minimal residual disease and assess treatment effectiveness.
Guideline-Based Recommendations
Diagnosis
- Utilize liquid biopsy for early detection of multiple cancers.
Management
- Incorporate liquid biopsy results into personalized therapy decisions.
Monitoring & Follow-up
- Monitor ctDNA levels post-treatment to identify residual disease.
Risks
- Consider challenges such as low availability of tumor-derived material and variability in sample handling.
Patient & Prescribing Data
Individuals undergoing cancer screening or treatment monitoring.
Liquid biopsy can provide insights into tumor dynamics and treatment responses earlier than traditional methods.
Clinical Best Practices
- Develop standardized workflows for liquid biopsy assays.
- Integrate computational tools for data analysis to enhance predictive performance.
Related Resources & Content
